{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:30Z","timestamp":1793734170499,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2020CFA065"],"award-info":[{"award-number":["2020CFA065"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFC1316200"],"award-info":[{"award-number":["2019YFC1316200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070124"],"award-info":[{"award-number":["82070124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcyt.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T15:47:55Z","timestamp":1681746475000},"page":"739-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-0629","authenticated-orcid":false,"given":"Wenjing","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongpei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2023.03.005_bib0001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0002","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0003","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-21-1075","article-title":"Targeting macrophages with CAR T cells delays solid tumor progression and enhances anti-tumor immunity","volume":"10","author":"Sanchez-Paulete","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6616391","article-title":"Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies","volume":"2021","author":"Tang","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0007","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jcyt.2018.07.005","article-title":"Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells","volume":"20","author":"Zolov","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/intimm\/11.5.667","article-title":"Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo","volume":"11","author":"Metzler","year":"1999","journal-title":"Int Immunol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0009","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2021-146293","article-title":"Chimeric Antigen Receptor T Cell Targeting to CD19 and CD22 Combined with Anti-PD-1 Antibody Induce High Response in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0010","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0011","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0013","article-title":"PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory\/Relapsed DLBCL: A Case Report","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0014","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0015","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-20-2487","article-title":"A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors","volume":"27","author":"Lei","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0016","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0018","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0019","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia","volume":"8","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jcyt.2023.03.005_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-136831","article-title":"Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed\/Refractory (R\/R) MCL in the ZUMA-2 Trial","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0021","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0024","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0025","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1111\/cas.14638","article-title":"Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro","volume":"111","author":"Liu","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"Journal of Immunotherapy"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0027","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0028","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0029","first-page":"67","article-title":"BTK signaling in B Cell Differentiation and Autoimmunity","volume":"393","author":"Corneth","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0030","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.2174\/092986711796150522","article-title":"Role of the non-receptor tyrosine kinase fes in cancer","volume":"18","author":"Condorelli","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0031","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/1078-0432.CCR-19-3003","article-title":"Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0032","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0033","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq-a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0034","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0036","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1038\/s41467-021-26844-1","article-title":"Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction","volume":"12","author":"Lamarth\u00e9e","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0038","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0039","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","article-title":"JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation","volume":"84","author":"Amano","year":"2016","journal-title":"Journal of Dermatological Science"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0041","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0042","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1126\/science.284.5414.638","article-title":"Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity","volume":"284","author":"Schaeffer","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0043","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1074-7613(00)80115-6","article-title":"Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells","volume":"11","author":"Fowell","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0044","doi-asserted-by":"crossref","first-page":"ra122","DOI":"10.1126\/scisignal.aab0949","article-title":"Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response","volume":"8","author":"Sun","year":"2015","journal-title":"Sci Signal"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-017-0486-z","article-title":"Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia","volume":"10","author":"Zhu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0046","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.179.6.3831","article-title":"Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter","volume":"179","author":"Gibson","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0047","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/imm.12686","article-title":"T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection","volume":"150","author":"Yi","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0048","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/eji.200939842","article-title":"T-bet, a Th1 transcription factor regulates the expression of Tim-3","volume":"40","author":"Anderson","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0049","doi-asserted-by":"crossref","first-page":"eabn7336","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0050","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41385-022-00487-x","article-title":"A Notch\/STAT3-driven Blimp-1\/c-Maf-dependent molecular switch induces IL-10 expression in human CD4(+) T cells and is defective in Crohn\u00b4s disease patients","volume":"15","author":"Ahlers","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0051","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.3390\/ijms19124118","article-title":"Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report","volume":"19","author":"Funk","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845499","article-title":"Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function","volume":"13","author":"Blaeschke","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0053","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jcyt.2023.03.005_bib0054","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492300066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492300066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:48:34Z","timestamp":1761443314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492300066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S146532492300066X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}